BiotechTube

APL-2

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Warm Autoimmune Hemolytic Anemia

Conditions

Warm Autoimmune Hemolytic Anemia, Cold Agglutinin Disease

Trial Timeline

Aug 31, 2017 → Sep 12, 2022

NCT ID
NCT03226678

About APL-2

APL-2 is a phase 2 stage product being developed by Apellis Pharmaceuticals for Warm Autoimmune Hemolytic Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03226678. Target conditions include Warm Autoimmune Hemolytic Anemia, Cold Agglutinin Disease.

What happened to similar drugs?

0 of 6 similar drugs in Warm Autoimmune Hemolytic Anemia were approved

Approved (0) Terminated (1) Active (5)
🔄Ianalumab + PlaceboNovartisPhase 3
🔄rituximab (Mabthera®) + PlaceboRochePhase 3
❌parsaclisinib + placeboIncytePhase 3
🔄Obexelimab + ObexelimabZenas BioPharmaPhase 3
🔄Fostamatinib disodiumRigel PharmaceuticalsPhase 3
🔄Fostamatinib disodium + PlaceboRigel PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT04085601Phase 3Completed
NCT03453619Phase 2Completed
NCT03226678Phase 2Completed

Competing Products

12 competing products in Warm Autoimmune Hemolytic Anemia

See all competitors
ProductCompanyStageHype Score
Ianalumab + PlaceboNovartisPhase 3
44
rituximab (Mabthera®) + PlaceboRochePhase 3
40
rilzabrutinibSanofiPhase 2
39
Isatuximab SAR650984SanofiPhase 2
27
parsaclisinib + placeboIncytePhase 3
29
RVT-1401 680 mg/weekly + RVT-1401 340 mg/weeklyImmunovantPhase 2
24
HMPL-523(300mg PO QD) + PlaceboHUTCHMEDPhase 2/3
36
Obexelimab + ObexelimabZenas BioPharmaPhase 3
38
ANX005AnnexonPhase 2
29
Fostamatinib 150 mg bidRigel PharmaceuticalsPhase 2
29
Fostamatinib disodiumRigel PharmaceuticalsPhase 3
41
Fostamatinib disodium + PlaceboRigel PharmaceuticalsPhase 3
34